What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma? episode artwork

EPISODE · Apr 29, 2025 · 5 MIN

What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma?

from Multiple Myeloma Hub

The Multiple Myeloma Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the impact of elranatamab on quality of life (QoL) in relapsed/refractory multiple myeloma (RRMM)? Mohty discussed the impact of elranatamab on QoL in patients with RRMM, highlighting its benefits in symptom relief, mobility, and overall well-being. Mohty also addressed the associated risk of cytokine release syndrome (CRS), neurotoxicity, and infections, concluding with the latest clinical trial data and emphasizing the need for ongoing research to optimize the role of elranatamab and other bispecific antibodies in patient care.  Key learningsOverall, elranatamab has positively impacted QoL in many patients with RRMM by providing rapid symptom relief, reducing bone pain and fatigue, improving mobility, and decreasing healthcare visits. Better disease control also contributes to improved psychological well-being. These benefits ultimately enhance daily functioning and overall well-being, allowing patients to resume their daily activities. Adverse events are a concern; however, the implementation of step-up dosing helps to reduce the risks of severe CRS and neurotoxicities. The risk of infections remains significant. However, mitigation strategies such as prophylactic antivirals, antifungals, and intravenous immunoglobulin administration can help preserve QoL. Clinical trial data from the MagnetisMM-3 (NCT04649359) trial support these findings, demonstrating improved patient-reported outcomes in global health status, functional ability, and symptom management. Ongoing trials aim to further clarify the role of elranatamab and other bispecific antibodies in enhancing QoL. This educational resource is independently supported by Pfizer. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.  Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Apr 29, 2025

Embed this episode

NOW PLAYING

What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma?

0:00 5:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Multiple Myeloma Hub?

This episode is 5 minutes long.

When was this Multiple Myeloma Hub episode published?

This episode was published on April 29, 2025.

Can I download this Multiple Myeloma Hub episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!